Composition, form of production and packaging
? Tablets chewing white or almost white, flat, round.
Levocarnitine 1 g
Excipients: mint flavor, flavoring liquorice, sucrose, magnesium stearate.
2 pcs. - Strips (5) - packs of cardboard.
? The solution for oral administration is clear, colorless.
1 f. (10 ml)
Levocarnitine 1 g
Excipients: malic acid (2-hydroxybutadionic acid), sodium benzoate, sodium saccharinate dihydrate, distilled water.
10 ml - bottles of dark glass (10) - cardboard boxes.
The solution for intravenous administration is clear, colorless.
1 ml of 1 amp.
Levokarnitina hydrochloride 246 mg 1.23 g,
in t.ch. Levocarnitine 200 mg 1 g
Auxiliary substances: water d / and.
5 ml - ampoules of dark glass (5) - plastic pallets (1) - cardboard packs.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
The drug for the correction of metabolic processes.
Levocarnitin is a natural substance related to the vitamins of group B. It participates in metabolic processes as a carrier of fatty acids through the cell membranes from the cytoplasm to the mitochondria, where these acids are subjected to the? -oxidation process with the formation of a large amount of metabolic energy (in the form of ATP).
The drug normalizes the protein and fat metabolism, restores the alkaline blood reserve, inhibits the formation of keto acids and anaerobic glycolysis, reduces the degree of lactic acidosis, and increases motor activity and increases the tolerance of exercise, while contributing to the economical consumption of glycogen and its increase in liver.
Suction and distribution
Levokarnitin is easily absorbed from the digestive tract, penetrates into all tissues of the body, the highest concentrations are created in skeletal muscles and myocardium. C max is achieved after 3 hours after administration, the therapeutic concentrations are maintained up to 9 hours.
It is excreted by the kidneys in unchanged form (more than 80% for 24 hours).
For oral administration
- primary and secondary deficiency of carnitine;
- disturbances of myocardial metabolism in IHD (angina pectoris, postinfarction state).
For intravenous administration
- secondary deficiency of carnitine;
- disturbances of myocardial metabolism against the background of acute myocardial infarction;
- the state of hypoperfusion due to cardiogenic shock.
At a primary and secondary deficiency of carnitine at genetic diseases the preparation is appointed inside. The dose is calculated depending on the age and body weight.
Age of Daily Dose
0-2 years of age 150 mg / kg body weight
2-6 years 100 mg / kg body weight
6-12 years of age 75 mg / kg body weight
over 12 years and adults 2-4 g
With a secondary deficiency in hemodialysis, the drug is administered orally at a dose of 2-4 g / day or iv in a dose of 2 g / day after a hemodialysis session.
With angina and postinfarction, inside appoint at a daily dose of 2-6 g / day. Before taking the contents of the vial with a single dose of the solution for oral administration should be dissolved in a glass of water and taken regardless of food intake.
In acute myocardial infarction, the daily dose is 100-200 mg / kg of body weight in the form of 4 slow IV injections or continuous IV injection during the first 48 hours, followed by a dose reduction of 2 times until the end of the patient's stay in the cardiac compartment. Then go to the oral administration of Carnitene in a dose of 2-6 g. With cardiogenic shock, IV administration should be continued until the patient leaves this condition.
In / in the drug should be administered slowly for 2-3 minutes.
On the part of the digestive system: with the use of the drug inside - light dispeptic disorders (pain in epigastrium, flatulence, diarrhea, constipation).
Other: allergic reactions; in patients with uremia - the symptoms of muscle weakness.
With a rapid IV injection of the drug (80 drops / min and more), pain along the vein can occur, with a decrease in the rate of administration.
- Hypersensitivity to the components of the drug.
With caution should prescribe the drug for diabetes.
PREGNANCY AND LACTATION
The drug can be used during pregnancy and during breastfeeding.
APPLICATION FOR CHILDREN
The drug is prescribed to children according to the indications and age.
The appointment of Carnitene to patients with diabetes mellitus may lead to the development of hypoglycemia as a result of improved glucose uptake. In this regard, during the administration of the drug should regularly monitor blood glucose and, if necessary, adjust the dose of hypoglycemic drugs and insulin.
There are no cases of habituation or metabolic dependence.
Toxic manifestations due to an overdose of levocarnitine have not been established.
SCS promotes the accumulation of the drug in tissues.
TERMS OF RELEASE FROM PHARMACY
A solution for intravenous administration is dispensed by prescription.
Chewable tablets and oral solution are allowed for use as a non-prescription drug.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of the reach of children at a temperature of up to 25 В° C. Shelf life of the chewing tablets is 3 years, the solution for oral administration is 5 years, the solution for intravenous administration is 4 years.